Table 6.
Expression of activation marker CD200 on memory, naïve, non-switched, switched, and total B lymphocytes
| Expression of CD200 on B lymphocytes | Median count (first quartile, third quartile) |
Statistical analysis (p-value) | |||||
|---|---|---|---|---|---|---|---|
| DUP− | DUP+ | Control | KW test p-value |
DUP+ versus DUP− | DUP− versus control | DUP+ versus control | |
| CD200 memory MFI | 4.53 | 4.13 | 3.90 | 0.055 | < 0.05 | ||
| (3.69, 5.61) | (3.87, 4.24) | (3.43, 4.41) | |||||
| CD200 memory, % | 39.0 | 44.0 | 34.0 | 0.755 | |||
| (23.0, 50.0) | (27.5, 51.0) | (24.0, 46.75) | |||||
| CD200 naïve MFI | 4.37 | 4.35 | 3.89 | 0.032 | < 0.05 | ||
| (3.75, 5.78) | (3. 90, 5.27) | (3.52, 4.38) | |||||
| CD200 naïve, % | 67.0 | 69.0 | 70.0 | 0.955 | |||
| (56.0, 80.0) | (62.0, 76.5) | (55.5, 79.0) | |||||
| CD200 non-switched MFI | 4.72 | 4.04 | 3.78 | 0.019 | < 0.05 | ||
| (3.89, 7.34) | (3.89, 5.51) | (3.50, 4.38) | |||||
| CD200 non-switched, % | 35.0 | 42.0 | 34.5 | 0.725 | |||
| (19.0, 54.0) | (32.5, 50.5) | (23.5, 50.5) | |||||
| CD200 switched MFI | 3.62 | 4.05 | 3.21 | 0.076 | < 0.05 | ||
| (2.79, 4.68) | (3.45, 5.05) | (3.02, 4.01) | |||||
| CD200 switched, % | 5.0 | 4.0 | 4.0 | 0.482 | |||
| (2.0, 7.0) | (2.5, 5.5) | (2.75, 5.0) | |||||
| CD200 total B lymphocytes MFI | 4.42 | 4.31 | 3.86 | 0.020 | < 0.05 | < 0.05 | |
| (3.73, 5.73) | (3.88, 5.34) | (3.52, 4.34) | |||||
| CD200 total B lymphocytes, % | 53.0 | 53.0 | 54.0 | 0.881 | |||
| (38.0, 62.0) | (43.5, 57.0) | (35.5–62.75) | |||||
DUP− patients without dupilumab treatment, DUP+ patients with dupilumab treatment, KW test results of Kruskal–Wallis test, MFI laboratory unit in flow cytometry. We show the significant difference in statistical analysis, p-value < 0.05